This phase II is evaluating the effective of combination therapy (encorafenib, cetuximab and pembrolizumab) compared to immunotherapy alone (pembrolizumab) in people with previously untreated metastatic bowel cancer.
This trial is treating patients with colorectal cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER
Eligible participants will be randomly allocated to either the Experimental Arm or Active Comparator Arm. in the Experimental Arm, participants will receive encorafenib (orally) plus cetuximab (intravenously) plus pembrolizumab (intravenously). In the Active Comparator Arm, participants will receive pembrolizumab alone (intravenously).
Recruiting Hospitals Read More